Rhythm beats as early HO launch shows strong traction amid rising spend concerns

 

Rhythm Pharma Q1 2026 revenue $60.1M (+84% YoY) beats estimates as early HO launch shows strong traction amid rising spend concerns

• Q1 revenue $60.1m, up 84% YoY and 5% QoQ; net loss per share $-0.83, EPS missing estimates.
• Early U.S. HO launch generated 150+ IMCIVREE start forms in six weeks, including ~40 trial conversions in acquired hypothalamic obesity.
• Roughly 110 HO prescribers to date, ~80% new to IMCIVREE, indicating broad engagement.
• International revenue rose 27% QoQ to $23.2m, driven by BBS and HO early-access markets.
• European HO approval obtained; country launches expected from 2027 after reimbursement and German G-BA processes.
• Japan HO NDA accepted and under PMDA review; company anticipates approval and launch by end of 2026.
• BBS base business showed steady prescription growth, temporarily masked by Q1 insurance-transition bridge-drug usage.
• Non-GAAP 2026 operating expense guidance reiterated at $385–415m, funding HO, Japan, and pipeline.
• SG&A reached $63.6m, up sharply YoY, reflecting sales force and marketing ramp.
• Management tone confident but cautious, emphasizing strong HO start yet acknowledging rare-disease launch unpredictability.
• Main concern: Sustainability of HO demand and payer coverage amid rising spend and rare-disease complexity.
• Strong quarter, driven by robust early HO launch indicators and expanding international HO footprint.

https://finviz.com/quote?t=RYTM&p=d